361 related articles for article (PubMed ID: 27825110)
21. Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling.
Yuan J; Wright G; Rosenwald A; Steidl C; Gascoyne RD; Connors JM; Mottok A; Weisenburger DD; Greiner TC; Fu K; Smith L; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Ott G; Vose JM; Staudt LM; Chan WC;
Am J Surg Pathol; 2015 Oct; 39(10):1322-30. PubMed ID: 26135560
[TBL] [Abstract][Full Text] [Related]
22. Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features.
Li M; Liu Y; Wang Y; Chen G; Chen Q; Xiao H; Liu F; Qi C; Yu Z; Li X; Fan L; Guo Y; Yan Q; Guo S; Wang Z
Am J Surg Pathol; 2017 Oct; 41(10):1322-1332. PubMed ID: 28319526
[TBL] [Abstract][Full Text] [Related]
23. MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.
Rovira J; Karube K; Valera A; Colomer D; Enjuanes A; Colomo L; Martínez-Trillos A; Giné E; Dlouhy I; Magnano L; Delgado J; Martínez A; Villamor N; Campo E; López-Guillermo A
Clin Cancer Res; 2016 Jun; 22(11):2755-64. PubMed ID: 26792260
[TBL] [Abstract][Full Text] [Related]
24. B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.
Xu PP; Zhong HJ; Huang YH; Gao XD; Zhao X; Shen Y; Cheng S; Huang JY; Chen SJ; Wang L; Zhao WL
EBioMedicine; 2017 Feb; 16():106-114. PubMed ID: 28153771
[TBL] [Abstract][Full Text] [Related]
25. SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients.
Schif B; Lennerz JK; Kohler CW; Bentink S; Kreuz M; Melzner I; Ritz O; Trümper L; Loeffler M; Spang R; Möller P
Oncotarget; 2013 Jan; 4(1):35-47. PubMed ID: 23296022
[TBL] [Abstract][Full Text] [Related]
26. p63 expression confers significantly better survival outcomes in high-risk diffuse large B-cell lymphoma and demonstrates p53-like and p53-independent tumor suppressor function.
Xu-Monette ZY; Zhang S; Li X; Manyam GC; Wang XX; Xia Y; Visco C; Tzankov A; Zhang L; Montes-Moreno S; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Parsons BM; Winter JN; Piris MA; Medeiros LJ; Young KH
Aging (Albany NY); 2016 Feb; 8(2):345-65. PubMed ID: 26878872
[TBL] [Abstract][Full Text] [Related]
27. [Significance of BCL6, MYC, P53 genes abnormalities for the prognosis of diffuse large B-cell lymphoma].
Gao P; Li Q; Wang Z; Yan F; Lu C; Cao X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Oct; 31(5):628-31. PubMed ID: 25297597
[TBL] [Abstract][Full Text] [Related]
28. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
[TBL] [Abstract][Full Text] [Related]
29. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
30. Clinical evaluation of panel testing by next-generation sequencing (NGS) for gene mutations in myeloid neoplasms.
Au CH; Wa A; Ho DN; Chan TL; Ma ES
Diagn Pathol; 2016 Jan; 11():11. PubMed ID: 26796102
[TBL] [Abstract][Full Text] [Related]
31. Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.
Peng CH; Liao CT; Ng KP; Tai AS; Peng SC; Yeh JP; Chen SJ; Tsao KC; Yen TC; Hsieh WP
Oncotarget; 2015 Aug; 6(23):19891-906. PubMed ID: 26087196
[TBL] [Abstract][Full Text] [Related]
32. [Investigation for pathological interpretation criteria and its prognostic value for P53 expression in Chinese diffuse large B-cell lymphoma].
Shi YF; Gao ZF; Li XH; Guo LG; Zheng QL; Long MP; Deng LJ; Du TT; Jia L; Zhao W; Song XX; Li M
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1010-1015. PubMed ID: 36709106
[No Abstract] [Full Text] [Related]
33. Prognostic impact of MYD88 and TP53 mutations in diffuse large B Cell lymphoma.
Ebid OAEH; Ezz El Arab LR; Saad AS; Ezz El Din M; Mostafa N; Swellam M
Ann Hematol; 2023 Dec; 102(12):3477-3488. PubMed ID: 37658234
[TBL] [Abstract][Full Text] [Related]
34. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study.
Young KH; Leroy K; Møller MB; Colleoni GW; Sánchez-Beato M; Kerbauy FR; Haioun C; Eickhoff JC; Young AH; Gaulard P; Piris MA; Oberley TD; Rehrauer WM; Kahl BS; Malter JS; Campo E; Delabie J; Gascoyne RD; Rosenwald A; Rimsza L; Huang J; Braziel RM; Jaffe ES; Wilson WH; Staudt LM; Vose JM; Chan WC; Weisenburger DD; Greiner TC
Blood; 2008 Oct; 112(8):3088-98. PubMed ID: 18559976
[TBL] [Abstract][Full Text] [Related]
35. Clinical implications of glutathione S-transferase genotyping in patients with diffuse large B-cell lymphoma.
Atanaskovic L; Cikota-Aleksic B; Tarabar O; Trimcev J; Zivanovic-Ivic A; Marjanovic S; Magic Z
J BUON; 2016; 21(6):1459-1465. PubMed ID: 28039708
[TBL] [Abstract][Full Text] [Related]
36. Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Svobodova K; Zemanova Z; Lhotska H; Novakova M; Podskalska L; Belickova M; Brezinova J; Sarova I; Izakova S; Lizcova L; Berkova A; Siskova M; Jonasova A; Cermak J; Michalova K
Leuk Res; 2016 Mar; 42():7-12. PubMed ID: 26851439
[TBL] [Abstract][Full Text] [Related]
37. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.
Karube K; Enjuanes A; Dlouhy I; Jares P; Martin-Garcia D; Nadeu F; Ordóñez GR; Rovira J; Clot G; Royo C; Navarro A; Gonzalez-Farre B; Vaghefi A; Castellano G; Rubio-Perez C; Tamborero D; Briones J; Salar A; Sancho JM; Mercadal S; Gonzalez-Barca E; Escoda L; Miyoshi H; Ohshima K; Miyawaki K; Kato K; Akashi K; Mozos A; Colomo L; Alcoceba M; Valera A; Carrió A; Costa D; Lopez-Bigas N; Schmitz R; Staudt LM; Salaverria I; López-Guillermo A; Campo E
Leukemia; 2018 Mar; 32(3):675-684. PubMed ID: 28804123
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
[TBL] [Abstract][Full Text] [Related]
39. Significance of TP53 mutations determined by next-generation "deep" sequencing in prognosis of estrogen receptor-positive breast cancer.
Uji K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Shimazu K; Kim SJ; Noguchi S
Cancer Lett; 2014 Jan; 342(1):19-26. PubMed ID: 23973262
[TBL] [Abstract][Full Text] [Related]
40. Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.
Forero-Castro M; Robledo C; Benito R; Bodega-Mayor I; Rapado I; Hernández-Sánchez M; Abáigar M; Maria Hernández-Sánchez J; Quijada-Álamo M; María Sánchez-Pina J; Sala-Valdés M; Araujo-Silva F; Kohlmann A; Luis Fuster J; Arefi M; de Las Heras N; Riesco S; Rodríguez JN; Hermosín L; Ribera J; Camos Guijosa M; Ramírez M; de Heredia Rubio CD; Barragán E; Martínez J; Ribera JM; Fernández-Ruiz E; Hernández-Rivas JM
Br J Cancer; 2017 Jul; 117(2):256-265. PubMed ID: 28557976
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
